Intracellular kinases play a ubiquitous role in signaling pathways within cells. Receptor tyrosine kinases function at the beginning of a number of signal transduction cascades, whereas ...

Background: This study examines the risks of hypertension and thrombotic events in NSCLC patients treated with Tyrosine Kinase Inhibitors (TKIs ... The epidermal growth factor receptor (EGFR), a ...

These include the Hippo pathway, Shh and Notch signaling and receptor tyrosine kinase signaling cascades such as EGFR/ErbB and TGF-β signaling (Drakulic et al., 2022). The molecular details on how ...

retriever generates disease-specific transcriptional drug response signatures by merging transcriptional signatures over time, concentration, and cell-type. These signatures can then be matched to ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

Fibroblast-like synoviocytes (FLS) from rats and patients with RA expressing or not Huntingtin-interacting protein 1 (HIP1) were studied for invasiveness, morphology and cell signalling. HIP1 knockout ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

TIE1, a receptor tyrosine kinase, was found to be upregulated by ... In conclusion, this work has identified a novel signaling pathway involving ING5, TIE1, and PDK1 Y163 phosphorylation that ...